Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Lamivudine to Telbivudine in Chronic Hepatitis B
NCT00132652Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Primary completion
- Dec 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of telbivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by Novartis. Primary endpoint: Therapeutic Response (Composite) at 52 weeks. Started Feb 2005; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00132652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132652.